Canada: Vanessa’s Law: What It Means For The Canadian Drug And Medical Device Industries

Last Updated: November 15 2014
Article by Sara Zborovski

Shhh, can you hear that? That’s the stamp of approval on a new era in Canadian drug and device regulation.

On November 6, 2014, Bill C-17 (the Protecting Canadians from Unsafe Drugs Act, aka Vanessa’s Law) (the “Act”) received Royal Assent and came into law. This new Act represents the most fundamental reform of the Canadian Food and Drugs Act in over five decades, and should act as a wakeup call to industry.

The Act significantly ups the ante on regulatory compliance, and affords the Minister of Health a number of new powers, all in the name of improved safety and increased transparency in connection with the sale of “therapeutic products”, defined as drugs, medical devices and any combination of the two (but not natural health products).

The Minister now has the power to obtain injunctions, order recalls of therapeutic products, order the collection and provision of post-market safety information, and order that changes be made to the labels and packaging of marketed products. In addition, the Act provides for the disclosure of confidential business information, without notice or consent, and significantly increased penalties for violations of the Act.

This bulletin provides an overview of some key changes to the regulation of drugs and medical devices imposed by the Act, and suggests measures industry can, and should, take in response.

New Oversight

The Act provides the Minister of Health with a number of new powers, all aimed at strengthening the oversight of therapeutic products throughout their life cycle.

Under the Act, where the Minister believes a therapeutic product may present a serious risk to human health, the Minister can order the provision of information within the person’s control to determine whether the product presents such a risk. In addition, at any time, the Minister can order the holder of a therapeutic product authorization to conduct an assessment of the product, including tests or studies, and to provide the results of that assessment to the Minister.

New Remedial Powers

Presumably, the new oversight measures provided in the Act will be used by the Minister to determine when and how to use the new remedial powers provided therein. For example, the Minister can now order any party that holds an authorization for the import or sale of a therapeutic product to modify the product’s label or modify or replace its package.

In addition, the Minister can now order anyone who sells a therapeutic product to recall it, upon belief that the product presents a serious or imminent risk of injury to health. Similarly, if the Minister is concerned that a person has done, or is about to commit an offence under the Act (including the sale of a recalled product), the Minister can seek an injunction from the court.

Disclosure of Confidential Business Information and Stricter Penalties

Perhaps two of the most talked-about aspects of the new regime imposed by the Act are the provisions around the disclosure of confidential business information, and the increased penalties provided for violations.

Given that one of the Act’s fundamental goals is to improve transparency around therapeutic products, it is no surprise that it provides for the disclosure of information relating to product safety. However, what has come as a surprise to some are the broad powers given to the Minister under the Act, and the broad definition of “confidential business information”.

Where the Minister believes a product may present a serious risk of injury to human health, the Act permits the disclosure of confidential business without notice to, or consent from, the person to whom the information relates. The very definition of confidential business information in the Act contemplates the disclosure of information that has actual or potential economic value, and it acknowledges that the disclosure of this information could result in a material financial loss to the disclosing person and material financial gain to its competitors.

Without a doubt, this provision has caused (or should cause) industry to sit up and take notice. Until now, the Canadian pharmaceutical and device industries have understood that any information submitted to Health Canada in connection with a regulatory submission is confidential and will be maintained as such - this may no longer be the case.

The second eye-opening change in the Act is the significantly higher penalties it introduces for non-compliance. Every person (including a person other than an individual, i.e. a corporation) who contravenes the Act as it relates to a therapeutic product, or contravenes an order made regarding the provision of additional information, modification or replacement of labelling or packaging, or a recall, is guilty of an offence and liable:

  • On conviction by indictment for a fine of up to $5,000,000 and/or up to two years in jail; and
  • On summary conviction for a fine of up to $250,000 and/or up to 6 months in jail (first offence) and a fine of up to $500,000 and/or up to 18 months in jail (subsequent offence).

Where a violation of the Act is made knowingly or recklessly, the fine on conviction by indictment is at the discretion of the court, with up to five years imprisonment. Harsher still, the Act provides that each day on which an offence is committed or continued constitutes a separate offence.

Of particular interest to corporations, the Act provides that where a person other than an individual commits an offence, any of the person’s directors, officers, agents or mandatories who directs, authorizes, assents to or acquiesces or participates in the commission of the offence is party to the offence and is liable on conviction to the punishment provided by the Act, even if the person is not prosecuted for the offence.

So What Now? Proceed with Caution

The Act provides for new regulation-making powers to give effect to the provisions contained therein. Accordingly, as with most new regulatory regimes, we can expect significant details and insight into how the new Act will actually impact the oversight of therapeutic products as regulations are introduced in the months and years to come.

However, some of the provisions of the Act came into force immediately upon Royal Assent, including the ability to require changes to labeling and packaging, the power of the Minister to seek an injunction and order a recall and the more stringent penalty provisions.

Accordingly, it is strongly recommended that all pharmaceutical and medical device companies operating in Canada take immediate stock of their compliance programs: the time to cross your t’s and dot your i’s has come. Companies should ensure that existing compliance programs account for these new developments, and where they don’t, programs should be updated. Employees should be trained on the implications of the new Act and to the extent they don’t already have one, companies should consider the addition of a Compliance Officer to the team.

Documenting a substantial compliance program is especially important given that companies and their directors and officers may avoid or mitigate the harsh penalties of the Act if they are able to show they exercised appropriate due diligence to comply with the Act.

In addition, distribution and sales agreements should be reviewed and amended as needed to ensure they provide for the required sharing of information. This is particularly relevant to importers, who may previously have only acted as “feet on the ground” in Canada, but who may now be called upon by the Minister to modify a product label or packaging.

Finally, given the changes around the ability of the Minister to disclose confidential business information, all companies, and particularly global companies, should review reporting mechanisms to ensure consistency in disclosure to regulatory authorities. Companies should also have a communications plan in place to protect against any negative publicity resulting from the disclosure of Health Canada activities.

Given that many powers afforded to the Minister in the Act are new, and the reach of these powers has not yet been tested, companies should be extra cautious in responding to requests made by the Minister under the Act, and should involve legal counsel (internal and/or external) at the earliest stage.

We will watch for proposed regulations, and will keep you apprised of developments through future Davis bulletins. In the meantime, if you have any questions about the Act or this bulletin, please contact the author.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions